BRITISH COLUMBIA, Canada, Aug. 7 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc., (TSX: IXS.V; OTC Bulletin Board: IXSBF) (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announced today that it has launched a large scale primate study of DXL625 (CD20), the company's lead program.
"We are beginning a study in cynomolgus monkeys of DXL625, an antibody directed against the B-cell marker CD20 and enhanced in potency with our DXL(TM) technology," said Thomas Kindt, Ph.D., Chief Scientific Officer. "The test is designed to evaluate toxicity and pharmokinetics of our product and to measure B-cell depletion and recovery in this primate species. This study, which takes multiple months to complete and is part of our drug development plan will generate data moving us toward human clinical trial testing with DXL625."
"Our scientific team has made steady progress in the rapid development of our first preclinical candidate, DXL625 for the prospective treatment of Non-Hodgkin's Lymphoma," said Jeff Morhet, CEO and Chairman. "The primate study is being conducted by Covance Inc. within their world-class facilities in Wisconsin. The launch of this study marks a significant milestone achievement for the company and our lead product DXL625."
InNexus recently announced the addition of a new product designated
DXLr120 (CD20). This is the third product added to the growing InNexus
pipeline and was developed using new recombinant methods to produce a
DXL(TM) anti-CD20 antibody. Upon questions regarding InNexus having a
franchise of CD20 products using multiple methods of creation, chemical and
recombinant, CEO Morhet said, "I would also think that these products could
and should be bundled toward future collaborations with pharmaceutical
companies and DXLr120 was developed within our part
|SOURCE InNexus Biotechnology Inc.|
Copyright©2008 PR Newswire.
All rights reserved